Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;12:651109. doi: 10.3389/fimmu.2021.651109

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 da Costa Gonçalves, Korevaar, Ortiz Virumbrales, Baan, Reinders, Merino, Lombardo and Hoogduijn.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MP uptake modulates HUVEC function under inflammatory conditions. HUVEC were primed with single or combined doses of 10 ng/ml TNFα and 50 ng/ml IFNγ. PKH-MP were added to the cells (ratio 1:50,000) and incubated for 24 h after which uptake was analyzed by flow cytometer. (A) Percentage of HUVEC positive for PKH-MP in different culture conditions. (B,C) HUVEC were separated from MP and assessed by flow cytometer and real-time RT-PCR after 48 h. (B) HUVEC surface levels of HLA-I, HLA-II, CD40, and CD144 and (C) mRNA expression of HUVEC for IL-6, IL-8, and endothelin after treated with MP under quiescent or TNFα + IFNγ conditions. Data are presented as mean ± SD from 6 experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. medium control or HUVEC without MP.